scholarly journals Sizing up stability: combination therapy with Apo-AI peptide mimetics and statins in systemic lupus erythematosus-mediated atherosclerosis

2010 ◽  
Vol 12 (5) ◽  
pp. 139 ◽  
Author(s):  
Yanice Mendez-Fernandez ◽  
Amy Major
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Combination Therapy ◽  
Lupus Erythematosus ◽  
Peptide Mimetics ◽  
Systemic Lupus ◽  
Apo Ai

Drug combination therapy of systemic lupus erythematosus

1994 ◽  
Vol 16 (2-3) ◽  
Author(s):  
PeterA. Miescher ◽  
Herv� Favre ◽  
Robert Lemoine ◽  
You-Peng Huang
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Combination Therapy ◽  
Lupus Erythematosus ◽  
Drug Combination ◽  
Systemic Lupus ◽  
Drug Combination Therapy

AB0377 Efficacy of tacrolimus combination therapy during the maintenance phase of systemic lupus erythematosus

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A902.3-A902
Author(s):  
K. Otsuka ◽  
Y. Miwa ◽  
M. Umemura ◽  
H. Tsukamoto ◽  
T. Tokunaga ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Combination Therapy ◽  
Lupus Erythematosus ◽  
Maintenance Phase ◽  
Systemic Lupus

Anti‐CXCL13 and anti‐TNF α combination therapy in a mouse model of systemic lupus erythematosus

2008 ◽  
Vol 22 (S2) ◽  
pp. 473-473
Author(s):  
Debra Bryce Gardner ◽  
Ashlyn Bassiri ◽  
Peter Bugelski ◽  
Robert Sarisky ◽  
Bailin Liang
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Combination Therapy ◽  
Mouse Model ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Tnf Α

scholarly journals EFFECTIVITY AND RENAL SAFETY OF CYCLOSPORINE AND METHYLPREDNISOLONE COMBINATION THERAPY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

2016 ◽  
Vol 51 (3) ◽  
pp. 156
Author(s):  
Desantika Wuryana ◽  
Bagus PP Suryana ◽  
Yulistiani Yulistiani
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Renal Function ◽  
Combination Therapy ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Side Effect ◽  
Systemic Lupus ◽  
Sledai Score ◽  
Function Tests ◽  
Renal Function Tests

Cyclosporine and methylprednisolone combination are second line therapy for moderate to severe systemic lupus erythemathosus. Some study suggest that the combination were effective to decrease of systemic lupus erythematosus disease activity. But record from the study, cyclosporine cause nephrotoxicity side effect. Therefore, this study should be considered to monitore therapy effect on disease activity and renal side effect. The aim of this study is to analyze the effect of cyclosporine and methylprednisolone combination therapy on disease activity in systemic lupus erythematosus (SLE) assessed by MEX-SLEDAI and renal side effect assessed by creatinine, ureum and proteinuria. A cohort, observational prospective study was conducted to determine the effect of cyclosporine and methylprednisolone combination therapy on disease activity of SLE and renal side effect of this combination. Patients who met criteria were given cyclosporine and methylprednisolone combination that normally renal function tests. MEX-SLEDAI score, creatinine, ureum and proteinuria were measured for fourth times (one time in one mounth), before study, 1st mounth, 2nd mounth, and 3rd mounth. The study comprised 9 patients SLE were given cyclosporine and methylprednisolone combination that normally renal function tests. All patients were female and had productive age. At 3rd mounth, there was increase patients who had MEX-SLEDAI score <2 (55,6%) and one patient (11,1%) had increase of creatinine, ureum and proteinuria. In conclusion, cyclosporine and methylprednisolone combination therapy showed the effectiveness and safety in 88,9% patients and renal dysfunction in 11,1% patients.

Successful tocilizumab and tacrolimus treatment in a patient with rheumatoid arthritis complicated by systemic lupus erythematosus

Lupus ◽  
2012 ◽  
Vol 21 (9) ◽  
pp. 1003-1006 ◽  
Author(s):  
K Maeshima ◽  
K Ishii ◽  
M Torigoe ◽  
C Imada ◽  
M Iwakura ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Combination Therapy ◽  
Lupus Erythematosus ◽  
Renal Involvement ◽  
Oral Prednisolone ◽  
Serum Levels ◽  
High Dose ◽  
Systemic Lupus ◽  
High Level

We report a 37-year-old female of intractable rheumatoid arthritis (RA) complicated by systemic lupus erythematosus (SLE), who was successfully treated with a combination of tocilizumab (TCZ) and tacrolimus. She was diagnosed with RA when she was 21 years old, and was administered oral prednisolone, injectable gold and salazosulfapyridine, but deformity of her hands gradually developed. She developed high fever and thrombocytopenia when she was 35 years old. Renal involvement, pericarditis, positive antinuclear antibody and high level of anti-double-stranded DNA antibody were found and the patient was diagnosed with SLE. Polyarthritis and immunological abnormalities developed despite aggressive immunosuppressive therapy including high-dose corticosteroids and intravenously administered cyclophosphamide. Tacrolimus (TAC) therapy gave only partial improvement of joint symptoms. After the initiation of combination therapy with TCZ, not only was a complete remission of RA obtained, but also the serum levels of SLE markers dramatically decreased. Our report suggests the possibility that this combination therapy is effective in treating SLE as well as RA.

Combination therapy for rheumatoid arthritis and drug-induced systemic lupus erythematosus

1994 ◽  
Vol 13 (3) ◽  
pp. 522-524 ◽  
Author(s):  
A. A. Borg ◽  
M. J. Davis ◽  
P. T. Dawes ◽  
M. F. Shadforth
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Combination Therapy ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Drug Induced
Sign in / Sign up

Export Citation Format

Share Document